ロード中...
ICIs治疗晚期非小细胞肺癌免疫相关不良事件的系统综述及Meta分析
BACKGROUND AND OBJECTIVE: In recent years, immune checkpoint inhibitors (ICIs) have become a hot spot in cancer because of their remarkable survival benefits on non-small cell lung cancer (NSCLC) patients. However, the immune-related adverse events (ir-AEs) induced by ICIs have been frequently repor...
保存先:
| 出版年: | Zhongguo Fei Ai Za Zhi |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
中国肺癌杂志编辑部
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7519956/ https://ncbi.nlm.nih.gov/pubmed/32752580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2020.104.07 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|